Frequent epigenetic alterations in polycomb repressive complex 2 in osteosarcoma cell lines

Helin Feng4,*, Heather Tillman2,*, Gang Wu3, Andrew M. Davidoff1 and Jun Yang1

1Department of Surgery, St Jude Children’s Research Hospital, Memphis, TN 38105, USA
2Department of Pathology, St Jude Children’s Research Hospital, Memphis, TN 38105, USA
3Department of Computational Biology, St Jude Children’s Research Hospital, Memphis, TN 38105, USA
4Department of Orthopedics, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei, People’s Republic of China

These authors contributed equally to this work

Correspondence to: Jun Yang, email: Jun.Yang2@stjude.org

Keywords: polycomb repressive complex 2; EZH2; osteosarcoma; H3K27me3

Abbreviations: PRC2: polycomb repressive complex 2; OS: osteosarcoma; H3K27me3: trimethylation of lysine 27 on histone H3

Received: April 01, 2018 Accepted: May 08, 2018 Published: June 05, 2018

ABSTRACT

Osteosarcoma (OS) cell lines are widely used in understanding the biological functions of cancer, identification and validation of therapeutic targets, as well as in vitro or in vivo preclinical drug screening. Here we report there is a frequent loss-of-function of polycomb repressive complex 2 (PRC2) in OS cell lines but it is rare in tumor samples based on genomic sequencing data, western blotting and immunohistochemistry analysis of H3K27me3. U2OS and 143B cell lines have a complete loss of function of PRC2 and several others have partial loss. In OS tumor tissues, only 1 out of 14 has low expression of H3K27me3. Kaplan-Meier analysis indicates that high EZH2, the component of PRC2, is associated with poor metastasis-free survival. Our observations are to raise the alarm that particular caution should be taken when using OS cell line models to study the disease, functional genomics, therapeutic target validation, drug screening, and epigenetic studies. Nevertheless, these cell lines will become useful biological tools to dissect the functions of PRC2.

INTRODUCTION

Osteosarcoma (OS) is the most prevalent primary bone tumor and has a high propensity to metastasize. Although the 5-year survival rate has increased from about 20% to 65–70% after the introduction of chemotherapy in the 1970s, no significant improvements have been made since then [1, 2]. Therefore, there is a pressing need to develop new agents for OS therapy. Although it is well known that genetic features of cell lines may not represent those of primary tumor cells in vivo, established OS cell lines are widely used in understanding the biological functions of cancer cells, identification and validation of therapeutic targets, as well as in vitro or in vivo preclinical drug screening. For example, U2OS is one of the most frequently used cell lines in cancer biology research and Google Scholar had at least 29,000 records for this cell line. Twenty years ago, cancer biologists realized that gene expression and phenotype, including drug response, vary greatly due to culture conditions and passage numbers. These differences are one explanation for variations in biological processes in the in vitro and in vivo settings, which causes difficulties for data reproducibility. Here we report a frequent loss-of-function of polycomb repressive complex 2 (PRC2) in OS cell lines. This observation appears to be a rare event in primary tumor samples, and therefore may be a unique feature of some OS cell lines.

PRC2 consists of 4 core proteins (EZH2, SUZ12, EED, and RbAp46/48) and epigenetically silences gene expression by adding repressive histone methyl marks on lysine 27 of histone H3 (H3K27) [3]. Although each component of PRC2 is important for its function, the histone methyltransferase
EZH2 is responsible for the catalytic activity. PRC2 is involved in various biological processes such as proliferation, differentiation, cell identity maintenance, and stem cell plasticity [3]. Overexpression of EZH2 promotes neoplastic transformation of normal prostatic cells and hyperplasia in the breast epithelium [4, 5], enhances tumor angiogenesis [6], invasion, and metastasis [7–9]. The importance of PRC2 in cancer has been further demonstrated by next generation sequencing of clinical cancer samples. Recurrent somatic mutations of EZH2 have been identified in subtypes of lymphoma, and EZH2 gain-of-function mutations alter substrate specificity for promoting hypertrimethylation of H3K27 [10]. However, the identification of loss-of-function mutations in PRC2 components in leukemia and in malignant peripheral nerve sheath tumors indicates that it also has tumor suppressive functions [11]. In addition, either gain or loss of function of PRC2 may lead to therapeutic resistance under different cellular context [12–16].

RESULTS

We have found a frequent loss-of-function of polycomb repressive complex 2 (PRC2) in OS cell lines after checking the genomic alterations of the cancer cell lines in Cancer Cell Line Encyclopedia(http://www.cbioportal.org) [17, 18]. Three out of 6 OS cell lines had genetic deletion in PRC2 components (Figure 1A), including HOS, U2OS and HS 888 T while MG63, SJSA-1 and T1-73 did not. Compared with other cell lines, OS cell lines ranked highest with 50% bearing genetic deletions of PRC2, while Ewing sarcoma cell lines were just below OS with 37.5% bearing genetic deletions of PRC2 (Figure 1B). Other lineages either had low frequencies of genetic amplifications or deletions of PRC2. We further examined the PRC2 function by Western blotting assessment of H3K27me3 in several OS cell lines and found that PRC2 had lost its function partially or completely in most of them (Figure 1C). The 143B cell line (>22,500 reference records on Google Scholar) has lost key components of the PRC2 complex including EZH2 and SUZ12, resulting in a total loss of H3K27me3/2 marks (Figure 1C). While the U2OS cell line appears to maintain expression of EZH2 from one allele, it has completely lost the ability to catalyze H3K27, suggesting an unidentified mechanism that modulates PRC2 activity is dysfunctional. Interestingly, the PRC2 complex in KHOS-240S and HOS cell lines are also dysfunctional by being unable to catalyze H3K27me3, although H3K27me2 is not remarkably affected (Figure 1C). Although it is not new cancer cells frequently have genetic alterations, our data clearly showed that only OS cell lines but not other lineages had genetic and protein deficiency in PRC2 complex, which is unique and important.

Recent genomic sequencing data from our institute and other studies show that osteosarcoma rarely has genetic alterations in the PRC2 complex (Supplementary Table 1) [19–21]. In our dataset, we found only EZH1, a paralogue of EZH2, had an in-frame deletion in 1 out of 23 cases although its impact on H3K27me3 was not assessed [21]. In Perry et al study, SUZ12 was found to have copy number loss and somatic mutation in only 1 out of 59 cases [20]. In Behjati et al study, EED was found to have mutation in 1 out of 112 tumors [22]. However, in Kovac [19] and Chiappetta [23] studies, no genetic alterations were identified in 92 tumors and 8 tumors, respectively. To assess H3K27me3 in tumor tissues, we performed immunohistochemistry for H3K27me3 in 14 cases of OS, 3 of which had adjacent normal tissue (Figure 1D and Supplementary Table 2). We found that nearly all osteosarcoma tissues bear detectable H3K27me3 (>50% nuclear positivity, Supplementary Table 2). However, one case showed low H3K27me3 levels compared with the adjacent normal tissue (15% vs 78.7% nuclear positivity, Figure 1D). These data seemed to be correlated with the RNA-seq data from OS tumor samples in that all tumors had detectable expression of PRC2 components [21] (Supplementary Figure 1). Although the clinical significance of H3K27me3 and PRC2 expression in OS needs to be further investigated by using a large cohort of cases, high EZH2 gene expression appeared to be correlated with a poor outcome in osteosarcoma (Supplementary Figure 2).

DISCUSSION

Despite the importance of PRC2 in cancer, functional studies of PRC2 in osteosarcoma are scarce. Nevertheless, our finding does not mean that the loss-of-function of PRC2 complex does not happen in vivo in OS. Although it is likely that the genetic/epigenetic loss-of-function of PRC2 in OS cells is due to selection under culture stress or intrinsic genetic instability, there is a third possibility that these cells were derived from rare clones that expanded when the cell lines were established using bulk tumor cells, especially for samples taken from relapsed, metastasized, or refractory disease. In the future, whether PRC2 is involved in metastasis of osteosarcoma warrants further studies. Our observations suggest more validation studies should be done when using OS cell line models to study the disease, functional genomics, therapeutic target validation, drug screening, and epigenetic studies.

Cell lines without detectable H3K27me3 have rarely been reported. Our discovery that OS cell lines have PRC2 function defects indicate these cell lines might be useful tools for further dissection of regulatory mechanisms of PRC2 mediated and independent functions. EZH2 has been reported to act as a transcriptional coactivator for androgen receptor [24], which is independent of its role in PRC2-mediated transcriptional repression. This functional switch is dependent on phosphorylation of EZH2 and requires an intact methyltransferase domain. Interestingly, recent studies have shown that EZH2 is subject to
Figure 1: Genetic alterations of PRC2 components in osteosarcoma cell lines. (A) The genetic amplification and deletion of PRC2 components in different histology cancers in CCLE data. The putative passenger mutations were not shown. (B) The percentage of genetic amplification/deletion of PRC2 components in different histology cancers in CCLE data. (C) Western blotting assessment of PRC2 complex and its epigenetic marks H3K27me2/me3 in osteosarcoma cell lines (SAOS2, KHOS-240S, MG63, HOS, U2OS, 143B), Ewing sarcoma cell line A673, and osteoblast cell line hFOB1.19 that was transfected with SV40 large T antigen. (D) Immunohistochemistry staining of H3K27me3 in 2 OS and adjacent normal tissues.
phosphorylation during G2/M phase of cell cycle by CDK1 and CDK2 [25–27], suggesting EZH2 function is incorporated into cell cycle regulation. EZH2 is able to methylate STAT3 to enhance its activity in glioblastoma stem cells [28, 29]. Yet EZH2 also has been shown to have methyltransferase activity-independent function in stabilizing BubR1 [30], a spindle assembly checkpoint protein, during mouse oocyte meiotic maturation. These studies further highlight that PRC2 and EZH2 regulation is highly context specific. Therefore, these unique cell lines may provide better insight into the novel biological functions of EZH2 or PRC2.

MATERIALS AND METHODS

Please see Supplementary Materials.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Ethics approval and consent to participate

The present study that evaluated paraffin-embedded osteosarcoma specimens was approved by the Human Ethics and Research Ethics Committees of the Fourth Hospital of Hebei Medical University. All patients provided written informed consent. The authors declare that they have no conflicts of interest.

Author contributions

JY conceived of the study. FH, HT, WG prepared and analyzed the data. JY and ADM wrote the manuscript. ADM, HT and GW edited the manuscript. All authors read and approved the final manuscript.

CONFLICTS OF INTEREST

None.

FUNDING

This work was supported by American Cancer Society-Research Scholar (J.Y., 130421-RSG-17-071-01-TBG), the National Cancer Institute (J.Y., R03 CA212802-01A1), the Assisi Foundation of Memphis, the American Lebanese Syrian Associated Charities (ALSAC), the US Public Health Service Childhood Solid Tumor Program Project Grant No. CA23099, the Cancer Center Support Grant No. 21766 from the National Cancer Institute, and the Key Project of Medical-Science Research of Hebei Province (HF, 20160159).

REFERENCES

1. Botter SM, Neri D, Fuchs B. Recent advances in osteosarcoma. Curr Opin Pharmacol. 2014; 16:15–23.
2. Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. J Clin Oncol. 2015; 33:3029–35.
3. Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature. 2011; 469:343–49.
4. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A. 2003; 100:11606–11.
5. Li X, Gonzalez ME, Toy K, Filzen T, Menajer SD, Kleer CG. Targeted overexpression of EZH2 in the mammary gland disrupts ductal morphogenesis and causes epithelial hyperplasia. Am J Pathol. 2009; 175:1246–54.
6. Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, Ravoori MK, Shahzad MM, Lee JW, et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell. 2010; 18:185–97.
7. Richter GH, Plehm S, Fasan A, Rössler S, Unland R, Bennani-Baiti IM, Hotfelder M, Löwel D, von Luetichau I, Mossbruger I, Quintanilla-Martinez L, Kovar H, Staegel MS, et al. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci U S A. 2009; 106:5324–29.
8. Ren G, Baritaki S, Marathe H, Feng J, Park S, Beach S, Bazeley PS, Beshir AB, Fenteany G, Mehra R, Daignault S, Al-Mulla F, Keller E, et al. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. Cancer Res. 2012; 72:3091–104.
9. Au SL, Wong CC, Lee JM, Fan DN, Tsang FH, Ng IO, Wong CM. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. Hepatology. 2012; 56:622–31.
10. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, Paul JE, Boyle M, Woolcock BW, Kuchenbauer F, Yap D, Humphries RK, Griffith OL, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010; 42:181–85.
11. Lee W, Teckie S, Wiesner T, Ran L, Prieto Granada CN, Lin M, Zhu S, Cao Z, Liang Y, Shoner A, Tap WD, Fletcher JA, Huberman KH, et al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet. 2014; 46:1227–32.
12. Gardner EE, Lok BH, Schneeeberger VE, Desmeules P, Miles LA, Arnold PK, Ni A, Khodos I, de Stanchina E,
Nguyen T, Sage J, Campbell JE, Ribich S, et al. Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis. Cancer Cell. 2017; 31:286–99.

13. Göllner S, Oellerich T, Agrawal-Singh S, Schenk T, Klein HU, Rohde C, Pabst C, Sauer T, Lerdrup M, Tavor S, Stölzel F, Herold S, Ehninger G, et al. Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia. Nat Med. 2017; 23:69–78.

14. Kikuchi J, Koyama D, Wada T, Izumi T, Hofgaard PO, Bogen B, Furukawa Y. Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma. J Clin Invest. 2015; 125:4375–90.

15. Tiffen JC, Gallagher SJ, Tseng HY, Filipp FV, Fazekas de St Groth B, Hersey P. EZH2 as a mediator of treatment resistance in melanoma. Pigment Cell Melanoma Res. 2016; 29:500–07.

16. Baker T, Nerle S, Pritchard J, Zhao B, Rivera VM, Garner A, Gonzalez F. Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors. Oncotarget. 2015; 6:32646–55. https://doi.org/10.18632/oncotarget.5066.

17. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2:401–04.

18. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6:pl1.

19. Kovac M, Blattmann C, Ribi S, Smida J, Mueller NS, Engert F, Castro-Giner F, Weischenfeldt J, Kovacova M, Krieg A, Androué D, Tunn PU, Dürr HR, et al. Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency. Nat Commun. 2015; 6:8940.

20. Perry JA, Kiezun A, Tonzi P, Van Allen EM, Carter SL, Baca SC, Cowley GS, Bhatt AS, Rheinbay E, Pedamallu CS, Helman E, Taylor-Weiner A, McKenna A, et al. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci U S A. 2014; 111:E5564–73.

21. Chen X, Bahrami A, Pappo A, Easton J, Dalton J, Hedlund E, Ellison D, Shurtleff S, Wu G, Wei L, Parker M, Rusch M, Nagahawatte P, et al, and St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Reports. 2014; 7:104–12.

22. Behjati S, Tarpey PS, Haase K, Ye H, Young MD, Alexandrov LB, Fardon SJ, Collord G, Wedge DC, Martincorea I, Cooke SL, Davies H, Mifsud W, et al. Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma. Nat Commun. 2017; 8:15936.

23. Chiappetta C, Mancini M, Lessi F, Aretini P, De Gregorio V, Puggioni C, Carletti R, Petrozza V, Civita P, Franceschi S, Naccarato AG, Rocca CD, Mazzanti CM, Di Cristofano A. Whole-exome analysis in osteosarcoma to identify a personalized therapy. Oncotarget. 2017; 8:30416–28. https://doi.org/10.18632/oncotarget.19010.

24. Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T, Xu H, Cato L, Thornton JE, et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science. 2012; 338:1465–69.

25. Wei Y, Chen YH, Li LY, Lang J, Yeh SP, Shi B, Yang CC, Yang JY, Lin CY, Lai CC, Hung MC. CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nat Cell Biol. 2011; 13:87–94.

26. Kaneko S, Li G, Son J, Xu CF, Margueron R, Neubert TA, Reimberg D. Phosphorylation of the PRC2 component Ezh2 is cell cycle-regulated and up-regulates its binding to ncRNA. Genes Dev. 2010; 24:2615–20.

27. Zeng X, Chen S, Huang H. Phosphorylation of EZH2 by CDK1 and CDK2: a possible regulatory mechanism of transmission of the H3K27me3 epigenetic mark through cell divisions. Cell Cycle. 2011; 10:579–83.

28. Methylation by EZH2 activates STAT3 in glioblastoma. Cancer Discov. 2013; 3:OF21.

29. Kim E, Kim M, Woo DH, Shin Y, Shin J, Chang N, Oh YT, Kim H, Rhee J, Nakano I, Lee C, Joo KM, Rich JN, et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell. 2013; 23:839–52.

30. Qu Y, Lu D, Jiang H, Chi X, Zhang H. EZH2 is required for mouse oocyte meiotic maturation by interacting with and stabilizing spindle assembly checkpoint protein BubRI. Nucleic Acids Res. 2016; 44:7659–72.